Adaptimmune Announces SPEAR T-cells™ Brand for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology

PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ: ADAP ), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company has adopted the name SPEAR T-cells™ (Specific Peptide Enhanced Affinity Receptor T-cells) to describe its proprietary technology.

The SPEAR T-cells brand is intended to symbolize the vital role that Adaptimmune’s enhanced affinity T-cell receptors play in targeting cancer.

Adaptimmune has a history of scientific leadership in the field of T-cell engineering and the company’s proprietary T-cell engineering platform, developed over the last 15 years, has generated a strong pipeline of T-cell therapies.

“Affinity optimized T-cell receptors are essential to the fight against cancer,” said James Noble, Adaptimmune’s Chief Executive Officer. “Our SPEAR T-cell technology is unique in delivering correctly identified targets and enhanced affinity TCRs that have the potency needed to attack tumors, but also the optimum specificity to minimize risks of cross-reactivity. Our proprietary technology provides us with ‘supra-natural’ TCRs that enable the acceleration of our programs and also facilitates our development of second generation TCRs.”

About Adaptimmune Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase I/II trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on October 13, 2015 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. 

Adaptimmune Contacts Will Roberts Vice President, Investor Relations T:  (215) 825-9306  E: will.roberts@adaptimmune.com Margaret Henry Head of PR T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 47

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 151

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 75

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 68

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
NTN Data Breach Raises Hard Questions Beyond Lawsuit

Updated Category News Views 124

Paperwork lifted from a factory network can become a very expensive loose bolt. NTN Bearing Corporation of America, a U.S. maker of bearings and automotive components, has reported a data-security incident that may have exposed sensitive information belonging to current and former employees. A law firm, Edelson Lechtzin LLP, is investigating potential class-action claims....

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading

Top 5 Most Recently Viewed Articles

Yonder Media Mobile Takes Legal Action Against FuboTV

Updated Category News Views 146

Yonder Media Mobile Initiates Lawsuit Against FuboTV In a recent announcement, Yonder Media Mobile Inc. ("YMM") has taken significant legal action against FuboTV, Inc. ("FuboTV"). This lawsuit contends that FuboTV has engaged in deceptive practices, causing substantial harm to YMM over an extended period. Serious Allegations of Misconduct The heart of the lawsuit revolves...

Continue Reading
United Airlines Stock Dive: It's Crazy but Predictable

Updated Category News Views 243

What's Happening With United Airlines Stock? So, here's the scoop: United Airlines Holdings, Inc. (NASDAQ:UAL) is trying to claw back into the green after a rough patch, you know? Just yesterday, it took a dive—down almost 6%—all thanks to those pesky rising fuel costs. Crude oil prices are hitting six-month highs again, and yeah, that's got investors sweating over...

Continue Reading
Fingerprint Cards' Management Boosts Confidence with New Investments

Updated Category News Views 136

Management's Bold Move in the Rights Issue Fingerprint Cards AB (publ) has taken a significant step in demonstrating their confidence in the company’s future. The CEO and CFO have decided to invest an impressive SEK 2 million in the ongoing rights issue without utilizing unit rights. This decision coincides with the company's efforts to raise approximately SEK 159.9...

Continue Reading
Investigation Launched for Aehr Test Systems, Inc. Investors

Updated Category News Views 200

Investigation for Aehr Test Systems, Inc. Investors Glancy Prongay & Murray LLP, a prominent national law firm specializing in shareholder rights, has officially commenced an investigation into Aehr Test Systems, Inc. (NASDAQ: AEHR) on behalf of investors. This initiative aims to scrutinize potential violations of federal securities laws by the company. Why the...

Continue Reading
Exciting Dual Reward Campaign by AB DAO and Bitget Unveiled

Updated Category News Views 180

AB DAO and Bitget Join Forces for a Rewarding Initiative AB DAO is thrilled to reveal its newest collaboration with Bitget, a prominent name in the digital asset trading sphere. This partnership has led to the creation of a dual reward campaign, aimed at boosting user engagement and enhancing the overall ecosystem. The campaign will distribute a staggering total of...

Continue Reading